The human immune system involves highly complex and coordinated processes in which
small proteins named cytokines play a key role. Cytokines have been implicated in the …

Objectives This meta-analysis investigates the efficacy of tumour necrosis factor α (TNFα)
blockers versus placebo for the treatment of ankylosing spondylitis (AS) and non …

Background TNF (tumor necrosis factor)‐alpha inhibitors block a key protein in the
inflammatory chain reaction responsible for joint inflammation, pain, and damage in …

Background Exercise is considered important in the management of patients with rheumatic
diseases, but the effect of high intensity exercises on disease activity is unknown. Objective …

Objective To assess the efficacy of etanercept in the treatment of early active nonsteroidal
antiinflammatory drug (NSAID)–refractory nonradiographic axial spondyloarthritis (SpA) …

Objectives To update the evidence for the efficacy and safety of (b) biological and (ts)
targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial …

This review evaluates the risk of tuberculosis (TB), adherence with recommendations for TB
prevention, and host-related risk in patients with rheumatoid arthritis (RA), psoriatic arthritis …

Background: Tumour necrosis factor (TNF)-α inhibitors (anti-TNFs) are typically used when
the inflammatory rheumatologic diseases ankylosing spondylitis (AS) and non-radiographic …

Biological agents directed against tumor necrosis factor (TNF) represent therapeutic options
for patients with ankylosing spondylitis with high disease activity despite use of non-steroidal …

With its approval more than 15 years ago, subcutaneous etanercept (Enbrel®) was the first
biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis …